Atorvastatin 80 mg daily + Atorvastatin 10 mg daily
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Saphenous Vein Graft Disease
Conditions
Saphenous Vein Graft Disease
Trial Timeline
Mar 1, 2012 → Jan 1, 2017
NCT ID
NCT01528709About Atorvastatin 80 mg daily + Atorvastatin 10 mg daily
Atorvastatin 80 mg daily + Atorvastatin 10 mg daily is a phase 3 stage product being developed by Pfizer for Saphenous Vein Graft Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01528709. Target conditions include Saphenous Vein Graft Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01528709 | Phase 3 | Completed |
Competing Products
2 competing products in Saphenous Vein Graft Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection | Regeneron Pharmaceuticals | Approved | 84 |